All In Biotech

Drug Trial Radar · NCT05110144

Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating the Efficacy of Two Doses of Duloxetine & Amitriptyline in Subjects With Refractory Chronic Cough

Last checked: Nov 20, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Nov 1, 2021

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with refractory chronic cough (RCC)

Conditions

  • Refractory Chronic Cough

Interventions

  • Duloxetine 30 MGDrug

    30mg orally for 4 weeks

  • Duloxetine 60 MGDrug

    60mg orally for 4 weeks

  • Amitriptyline 25 MGDrug

    25 mg orally for 4 weeks

  • Amitriptyline 50 MGDrug

    50 mg orally for 4 weeks

  • Placebo 30 MGDrug

    30mg tablet with no active study ingredient for 4 weeks

  • Placebo 60 MGDrug

    60mg tablet with no active study ingredient for 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in awake objective cough frequency (at 4 & 8 weeks)Time frame: 4 weeks, 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.